At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly › Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Shares of Eli Lilly ( LLY -2.30%) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for ...

Over the past five years, Eli Lilly stock has risen roughly 320% as of market close Aug. 11. Meanwhile, the company has delivered a dividend-adjusted total return of roughly 347% over the last five ...

Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Weaker-than-expected guidance sent the stock price down significantly. Even so, Lilly grew revenue by 45% year over year to $12.7 billion.

Eli Lilly reported strong earnings for the second quarter, beating on the top and bottom lines. Disappointing trial results for orforglipron led to a sharp crash in its share price on Thursday.